Cannabis Bioscience International Holdings Reports 28.2% Revenue Decline and Increased Losses for Quarter Ending November 30, 2025

Cannabis Bioscience International Holdings, Inc. reported a significant decline in financial performance for the quarter ending November 30, 2025, compared to the same period in the previous year. The company generated revenues of $53,266, a decrease of 28.2% from $74,248 in the prior year. This decline was primarily attributed to a reduction in clinical trial contracts, which fell from $73,781 to $40,903. The company's gross profit also decreased to $42,766 from $66,445, reflecting the impact of lower revenues and increased costs associated with revenue generation.

The company's operating expenses increased to $138,643 from $126,072, driven largely by a rise in professional fees, which surged from $7,112 to $52,035. As a result, the operating loss widened to $95,877 from $59,627 in the previous year. The net loss for the quarter was $116,966, compared to a loss of $79,528 in the same quarter of 2024. The company’s accumulated deficit increased to $6,082,513 as of November 30, 2025, up from $5,882,901 at the end of the previous fiscal year.

In terms of operational metrics, the company reported a negative working capital of $1,113,695, indicating ongoing liquidity challenges. Cash and cash equivalents were notably low at $132, down from $12,952 at the end of May 2025. Accounts receivable increased to $21,811 from $6,380, suggesting potential delays in cash collection. The company has not generated sufficient income to cover its operating expenses since its inception, raising concerns about its ability to continue as a going concern.

Strategically, Cannabis Bioscience International Holdings has been focusing on expanding its operations and raising capital to support its business model, which includes clinical trials, educational services, and CBD product sales. However, the company has faced challenges in executing its operating plan, as evidenced by the termination of its Pharmacology University business on December 31, 2025. The company is also grappling with high levels of related-party payables, which totaled $793,196 as of November 30, 2025, compared to $623,474 at the end of May 2025.

Looking ahead, the company acknowledges the need for substantial additional capital to fund its operations and repay debts. Management has indicated that the ability to continue as a going concern is contingent upon successfully executing its operational strategies and securing financing. The company has not provided specific guidance on future revenue expectations, but it remains focused on improving its financial condition through potential new service offerings and market expansion.